{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T02:11:07Z","timestamp":1776219067205,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ebiom.2025.106067","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:22:35Z","timestamp":1765279355000},"page":"106067","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Preclinical evaluation of long-acting cabotegravir and rilpivirine for HIV post-exposure prophylaxis in a macaque model"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8426-6532","authenticated-orcid":false,"given":"Priya","family":"Srinivasan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jining","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiancheng","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuong","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayanna","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Little","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyana","family":"Singletary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Deyounks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Lipscomb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athena P.","family":"Kourtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid","family":"Heneine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6437-7745","authenticated-orcid":false,"given":"J. Gerardo","family":"Garc\u00eda-Lerma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ebiom.2025.106067_bib2","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","article-title":"Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study","volume":"14","author":"Grant","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"27","key":"10.1016\/j.ebiom.2025.106067_bib3","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ebiom.2025.106067_bib4","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1016\/S2352-3018(21)00071-0","article-title":"Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Ogbuagu","year":"2021","journal-title":"Lancet HIV"},{"issue":"12","key":"10.1016\/j.ebiom.2025.106067_bib5","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2018.1917","article-title":"HIV preexposure prophylaxis: a review","volume":"319","author":"Riddell","year":"2018","journal-title":"JAMA"},{"issue":"10337","key":"10.1016\/j.ebiom.2025.106067_bib6","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"Delany-Moretlwe","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ebiom.2025.106067_bib7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2025.106067_bib8","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-Yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women","volume":"391","author":"Bekker","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ebiom.2025.106067_bib9","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","article-title":"Twice-Yearly lenacapavir for HIV prevention in men and gender-diverse persons","volume":"392","author":"Kelley","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2025.106067_bib10","series-title":"Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV\u2014United States, 2016","author":"Dominguez","year":"2016"},{"key":"10.1016\/j.ebiom.2025.106067_bib11","series-title":"Guidelines for HIV post-exposure prophylaxis","year":"2024"},{"key":"10.1016\/j.ebiom.2025.106067_bib12","series-title":"HIV post-exposure prophylaxis prescription trends: united States, 2013-2022","author":"Tanner","year":"2024"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106067_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7401a1","article-title":"Antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV - CDC recommendations, United States, 2025","volume":"74","author":"Tanner","year":"2025","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.ebiom.2025.106067_bib15","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1126\/science.270.5239.1197","article-title":"Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine","volume":"270","author":"Tsai","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2025.106067_bib16","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1128\/JVI.72.5.4265-4273.1998","article-title":"Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment","volume":"72","author":"Tsai","year":"1998","journal-title":"J Virol"},{"issue":"18","key":"10.1016\/j.ebiom.2025.106067_bib17","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1097\/QAD.0000000000000505","article-title":"Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis","volume":"28","author":"Ford","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.ebiom.2025.106067_bib18","series-title":"The national intimate partner and sexual violence survey: 2015 data brief\u2013updated release","author":"Smith","year":"2018"},{"key":"10.1016\/j.ebiom.2025.106067_bib19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/sextrans-2011-050371","article-title":"Adherence to HIV post-exposure prophylaxis in victims of sexual assault: a systematic review and meta-analysis","volume":"88","author":"Chacko","year":"2012","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.ebiom.2025.106067_bib20","series-title":"Long-Acting injectable CAB\/RPV is superior to oral ART in PWH with adherence challenges: ACTG A5359","author":"Rana","year":"2023"},{"issue":"12","key":"10.1016\/j.ebiom.2025.106067_bib21","doi-asserted-by":"crossref","first-page":"7349","DOI":"10.1128\/JVI.79.12.7349-7354.2005","article-title":"Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1","volume":"79","author":"North","year":"2005","journal-title":"J Virol"},{"issue":"11","key":"10.1016\/j.ebiom.2025.106067_bib22","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1128\/JVI.76.11.5803-5806.2002","article-title":"A nucleotide substitution in the tRNA(Lys) primer binding site dramatically increases replication of recombinant simian immunodeficiency virus containing a human immunodeficiency virus type 1 reverse transcriptase","volume":"76","author":"Soderberg","year":"2002","journal-title":"J Virol"},{"issue":"18","key":"10.1016\/j.ebiom.2025.106067_bib23","doi-asserted-by":"crossref","first-page":"8210","DOI":"10.1073\/pnas.92.18.8210","article-title":"Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors","volume":"92","author":"Uberla","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.ebiom.2025.106067_bib24","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1006\/bbrc.1995.1890","article-title":"Sensitivity\/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors","volume":"211","author":"Balzarini","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"issue":"6175","key":"10.1016\/j.ebiom.2025.106067_bib25","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1126\/science.1248707","article-title":"Long-acting integrase inhibitor protects macaques from intrarectal simian\/human immunodeficiency virus","volume":"343","author":"Andrews","year":"2014","journal-title":"Science"},{"issue":"270","key":"10.1016\/j.ebiom.2025.106067_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010297","article-title":"The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge","volume":"7","author":"Radzio","year":"2015","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106067_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54783-0","article-title":"SHIV remission in macaques with early treatment initiation and ultra long-lasting antiviral activity","volume":"15","author":"Daly","year":"2024","journal-title":"Nat Commun"},{"issue":"10267","key":"10.1016\/j.ebiom.2025.106067_bib28","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ebiom.2025.106067_bib29","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/hiv.12247","article-title":"Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers","volume":"16","author":"Verloes","year":"2015","journal-title":"HIV Med"},{"issue":"2","key":"10.1016\/j.ebiom.2025.106067_bib30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/QAD.0000000000003059","article-title":"Sexually transmitted infections and depot medroxyprogesterone acetate do not impact protection from simian HIV acquisition by long-acting cabotegravir in macaques","volume":"36","author":"Vishwanathan","year":"2022","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106067_bib31","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41467-023-36330-5","article-title":"Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection","volume":"14","author":"Young","year":"2023","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.ebiom.2025.106067_bib32","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1086\/507306","article-title":"Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges","volume":"194","author":"Subbarao","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ebiom.2025.106067_bib33","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.chom.2023.01.016","article-title":"Antiretroviral therapy reveals triphasic decay of intact SIV genomes and persistence of ancestral variants","volume":"31","author":"Fray","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ebiom.2025.106067_bib34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jim.2017.07.008","article-title":"A multiplex assay for detection of SHIV plasma and mucosal IgG and IgA","volume":"450","author":"Parker","year":"2017","journal-title":"J Immunol Methods"},{"issue":"11","key":"10.1016\/j.ebiom.2025.106067_bib35","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/infdis\/jiz383","article-title":"Efficacy of oral Tenofovir Alafenamide\/Emtricitabine combination or single-agent Tenofovir Alafenamide against vaginal simian human immunodeficiency virus infection in macaques","volume":"220","author":"Massud","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ebiom.2025.106067_bib36","series-title":"Guide for the care and use of laboratory animals","year":"2011"},{"issue":"30","key":"10.1016\/j.ebiom.2025.106067_bib37","first-page":"2020","article-title":"AVMA guidelines for the euthanasia of animals: 2020 edition","volume":"2013","author":"Underwood","year":"2020"},{"key":"10.1016\/j.ebiom.2025.106067_bib38","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1111\/bcp.14980","article-title":"Multicompartmental pharmacokinetic evaluation of long-acting cabotegravir in healthy adults for HIV preexposure prophylaxis","volume":"88","author":"Shaik","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ebiom.2025.106067_bib39","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1093\/jac\/dkab338","article-title":"Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV","volume":"76","author":"Neyens","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"7742","key":"10.1016\/j.ebiom.2025.106067_bib40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","article-title":"A quantitative approach for measuring the reservoir of latent HIV-1 proviruses","volume":"566","author":"Bruner","year":"2019","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ebiom.2025.106067_bib41","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.4156","article-title":"Defective proviruses rapidly accumulate during acute HIV-1 infection","volume":"22","author":"Bruner","year":"2016","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ebiom.2025.106067_bib42","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","article-title":"Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure","volume":"155","author":"Ho","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2025.106067_bib43","author":"Smith"},{"key":"10.1016\/j.ebiom.2025.106067_bib44","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/infdis\/jiad520","article-title":"Viral load dynamics in plasma and semen when antiretroviral therapy is initiated during early HIV-1 infection","volume":"229","author":"Gilada","year":"2024","journal-title":"J Infect Dis"},{"issue":"19","key":"10.1016\/j.ebiom.2025.106067_bib45","doi-asserted-by":"crossref","first-page":"10406","DOI":"10.1128\/JVI.01155-10","article-title":"Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys","volume":"84","author":"Liu","year":"2010","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.ebiom.2025.106067_bib46","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1128\/AAC.00350-08","article-title":"Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects","volume":"52","author":"Van Rompay","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.ebiom.2025.106067_bib47","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1089\/aid.2018.0265","article-title":"A multiple dose phase 1 assessment of rilpivirine long acting in a model of preexposure prophylaxis against HIV","volume":"35","author":"Cranston","year":"2019","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"3","key":"10.1016\/j.ebiom.2025.106067_bib48","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/clpt.2014.118","article-title":"A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis","volume":"96","author":"Jackson","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ebiom.2025.106067_bib49","article-title":"Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland","volume":"36","author":"Thoueille","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106067_bib50","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1038\/s41467-018-07881-9","article-title":"Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy","volume":"9","author":"Whitney","year":"2018","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.ebiom.2025.106067_bib51","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nri1706","article-title":"Perils at mucosal front lines for HIV and SIV and their hosts","volume":"5","author":"Haase","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.ebiom.2025.106067_bib52","article-title":"Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP","volume":"68","author":"Han","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"13","key":"10.1016\/j.ebiom.2025.106067_bib53","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMc2402088","article-title":"Features of HIV infection in the context of long-acting Cabotegravir Preexposure prophylaxis","volume":"391","author":"Landovitz","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ebiom.2025.106067_bib54","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMc1413931","article-title":"Viremic relapse after HIV-1 remission in a perinatally infected child","volume":"372","author":"Luzuriaga","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2025.106067_bib55","series-title":"CAB\/RPV LA package insert","year":"2021"},{"issue":"11","key":"10.1016\/j.ebiom.2025.106067_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/v16111715","article-title":"Spectrum of non-nucleoside reverse transcriptase inhibitor-associated drug resistance mutations in persons living with HIV-1 receiving rilpivirine","volume":"16","author":"Nagarajan","year":"2024","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.ebiom.2025.106067_bib57","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/infdis\/jiv528","article-title":"Selection of rilpivirine-resistant HIV-1 in a seroconverter from the SSAT 040 trial who received the 300-mg dose of long-acting rilpivirine (TMC278LA)","volume":"213","author":"Penrose","year":"2016","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.ebiom.2025.106067_bib58","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx061","article-title":"Differentiating nonoccupational postexposure prophylaxis seroconverters and non-seroconverters in a community-based Clinic in Los Angeles, California","volume":"4","author":"Beymer","year":"2017","journal-title":"Open Forum Infect Dis"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425005110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425005110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:51:40Z","timestamp":1773877900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396425005110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":56,"alternative-id":["S2352396425005110"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.106067","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of long-acting cabotegravir and rilpivirine for HIV post-exposure prophylaxis in a macaque model","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.106067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106067"}}